ProKidney Corp.
NASDAQ:PROKBiotechnology
Healthcare
$1.04 +0.86%
+$0.02 today
- Market cap
- $349.70M
- Beta
- 1.70
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.53
52W Low $0.54High $7.13
Volume 1.80M
Average 0.96M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$120.12M
FY 2025 · Annual
Investing Cash Flow
$103.97M
FY 2025 · Annual
+409.3% YoYFinancing Cash Flow
$25.57M
FY 2025 · Annual
-82.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (55.15M) | (148.14M) | (135.45M) | (163.34M) | (151.61M) |
| Depreciation & Amortization | 1.98M | 3.04M | 3.85M | 5.43M | 6.58M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 699K | 74.47M | 30.85M | 29.37M | 25.34M |
| Change in Working Capital | 2.16M | (6.46M) | 16.67M | 3.96M | 1.28M |
| Accounts Receivables | 0 | 0 | (1.38M) | (1.07M) | 1.32M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 5K | 494K | 11.64M | 11.59M | (5.92M) |
| Other Working Capital | 2.16M | (6.95M) | 6.41M | (6.56M) | 5.88M |
| Other Non-Cash Items | 0 | 0 | (6M) | (1.78M) | (1.7M) |
| Operating Cash Flow | (50.3M) | (77.09M) | (90.07M) | (126.35M) | (120.12M) |
| Capital Expenditures | (5.19M) | (1.85M) | (34.2M) | (29.51M) | (15.2M) |
| Acquisitions (Net) | 1K | 108K | 0 | 0 | 18.22M |
| Purchases of Investments | 0 | 0 | (471.6M) | (324.02M) | (217.08M) |
| Sales of Investments | 0 | 0 | 175.82M | 373.95M | 318.02M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (5.19M) | (1.74M) | (329.98M) | 20.41M | 103.97M |
| Debt Repayment | (30K) | (32K) | (52K) | (54K) | (26K) |
| Common Stock Issued | 71.5M | 6.05M | 0 | 144.32M | 25.6M |
| Common Stock Repurchased | 0 | 0 | (9.5M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 542.5M | 0 | 140K | 0 |
| Financing Cash Flow | 71.47M | 548.52M | (9.55M) | 144.41M | 25.57M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 15.98M | 469.69M | (429.6M) | 38.47M | 9.42M |
| Free Cash Flow | (55.49M) | (78.94M) | (124.27M) | (155.86M) | (135.31M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$151.6M
+ D&A$6.6M
+ Stock-Based Comp$25.3M
+ Deferred Tax$0
+ Working Capital$1.3M
- Other Non-Cash-$1.7M
= Operating Cash Flow-$120.1M
- Capex-$15.2M
= Free Cash Flow-$135.3M
Analysis
FY2025 free cash flow is -$135.3M. FCF conversion is 89.2% of net income. Operating cash flow was -$120.1M, with capex of -$15.2M. The largest bridge item is Stock-Based Comp at $25.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 424B5 | 424B5 filing | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| EFFECT | EFFECT filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 |
Does PROK generate free cash flow?
ProKidney Corp. (PROK) generated -$135.31M of free cash flow in fiscal 2025.
How much operating cash flow does PROK produce?
Operating cash flow was -$120.12M, before capital expenditures of $15.20M.
Continue the stock analysis
Jump to another research area for this company.